Literature DB >> 12601109

Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.

J W Day1, K Ricker, J F Jacobsen, L J Rasmussen, K A Dick, W Kress, C Schneider, M C Koch, G J Beilman, A R Harrison, J C Dalton, L P W Ranum.   

Abstract

BACKGROUND: Myotonic dystrophy types 1 (DM1) and 2 (DM2/proximal myotonic myopathy PROMM) are dominantly inherited disorders with unusual multisystemic clinical features. The authors have characterized the clinical and molecular features of DM2/PROMM, which is caused by a CCTG repeat expansion in intron 1 of the zinc finger protein 9 (ZNF9) gene.
METHODS: Three-hundred and seventy-nine individuals from 133 DM2/PROMM families were evaluated genetically, and in 234 individuals clinical and molecular features were compared.
RESULTS: Among affected individuals 90% had electrical myotonia, 82% weakness, 61% cataracts, 23% diabetes, and 19% cardiac involvement. Because of the repeat tract's unprecedented size (mean approximately 5,000 CCTGs) and somatic instability, expansions were detectable by Southern analysis in only 80% of known carriers. The authors developed a repeat assay that increased the molecular detection rate to 99%. Only 30% of the positive samples had single sizeable expansions by Southern analysis, and 70% showed multiple bands or smears. Among the 101 individuals with single expansions, repeat size did not correlate with age at disease onset. Affected offspring had markedly shorter expansions than their affected parents, with a mean size difference of -17 kb (-4,250 CCTGs).
CONCLUSIONS: DM2 is present in a large number of families of northern European ancestry. Clinically, DM2 resembles adult-onset DM1, with myotonia, muscular dystrophy, cataracts, diabetes, testicular failure, hypogammaglobulinemia, and cardiac conduction defects. An important distinction is the lack of a congenital form of DM2. The clinical and molecular parallels between DM1 and DM2 indicate that the multisystemic features common to both diseases are caused by CUG or CCUG expansions expressed at the RNA level.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601109     DOI: 10.1212/01.wnl.0000054481.84978.f9

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  113 in total

1.  Cerebral and muscle MRI abnormalities in myotonic dystrophy.

Authors:  Daniel T Franc; Ryan L Muetzel; Paul R Robinson; Craig P Rodriguez; Joline C Dalton; Cameron E Naughton; Bryon A Mueller; Jeffrey R Wozniak; Kelvin O Lim; John W Day
Journal:  Neuromuscul Disord       Date:  2012-01-30       Impact factor: 4.296

2.  [Musculoskeletal pain as the most prominent feature in myotonic dystrophy type 2].

Authors:  A George; C Schneider-Gold; K Reiners; C Sommer
Journal:  Schmerz       Date:  2006-09       Impact factor: 1.107

3.  Reduction of Cellular Nucleic Acid Binding Protein Encoded by a Myotonic Dystrophy Type 2 Gene Causes Muscle Atrophy.

Authors:  Christina Wei; Lauren Stock; Christiane Schneider-Gold; Claudia Sommer; Nikolai A Timchenko; Lubov Timchenko
Journal:  Mol Cell Biol       Date:  2018-06-28       Impact factor: 4.272

4.  Large pathogenic expansions in the SCA2 and SCA7 genes can be detected by fluorescent repeat-primed polymerase chain reaction assay.

Authors:  Claudia Cagnoli; Giovanni Stevanin; Chiara Michielotto; Giovanni Gerbino Promis; Alessandro Brussino; Patrizia Pappi; Alexandra Durr; Elisa Dragone; Michelle Viemont; Cinzia Gellera; Alexis Brice; Nicola Migone; Alfredo Brusco
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

5.  Case 12: my doctor says that I have ALS!

Authors:  Robin K Wilson; Vinay Chaudhry
Journal:  MedGenMed       Date:  2006-03-22

6.  Diagnostic odyssey of patients with myotonic dystrophy.

Authors:  James E Hilbert; Tetsuo Ashizawa; John W Day; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  J Neurol       Date:  2013-06-27       Impact factor: 4.849

7.  Early onset posterior subscapular cataract in a series of myotonic dystrophy type 2 patients.

Authors:  C Papadopoulos; K Kekou; S Xirou; S Kitsiou-Tzeli; E Kararizou; G K Papadimas
Journal:  Eye (Lond)       Date:  2017-12-08       Impact factor: 3.775

8.  Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect.

Authors:  Linda L Bachinski; Bjarne Udd; Giovanni Meola; Valeria Sansone; Guillaume Bassez; Bruno Eymard; Charles A Thornton; Richard T Moxley; Peter S Harper; Mark T Rogers; Karin Jurkat-Rott; Frank Lehmann-Horn; Thomas Wieser; Josep Gamez; Carmen Navarro; Armand Bottani; Andre Kohler; Mark D Shriver; Riitta Sallinen; Maija Wessman; Shanxiang Zhang; Fred A Wright; Ralf Krahe
Journal:  Am J Hum Genet       Date:  2003-09-10       Impact factor: 11.025

Review 9.  Recent advances in myotonic dystrophy type 2.

Authors:  Christina M Ulane; Sarah Teed; Jacinda Sampson
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

10.  Reduction of the rate of protein translation in patients with myotonic dystrophy 2.

Authors:  Claudia Huichalaf; Benedikt Schoser; Christiane Schneider-Gold; Bingwen Jin; Partha Sarkar; Lubov Timchenko
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.